|
J Biol Chem, Vol. 275, Issue 19, 14231-14241, May 12, 2000
Cdc42-induced Activation of the Mixed-Lineage Kinase SPRK
in Vivo
REQUIREMENT OF THE Cdc42/Rac INTERACTIVE BINDING MOTIF AND
CHANGES IN PHOSPHORYLATION*
Barbara C.
Böck §,
Panayiotis O.
Vacratsis ¶,
Erion
Qamirani¶ , and
Kathleen A.
Gallo§¶**
From the Departments of § Physiology and
¶ Biochemistry, Michigan State University,
East Lansing, Michigan 48824
 |
ABSTRACT |
Src homology 3 domain (SH3)-containing
proline-rich protein kinase (SPRK)/mixed-lineage kinase (MLK)-3 is a
serine/threonine kinase that upon overexpression in mammalian cells
activates the c-Jun NH2-terminal kinase pathway. The
mechanisms by which SPRK activity is regulated are not well understood.
The small Rho family GTPases, Rac and Cdc42, have been shown to bind
and modulate the activities of signaling proteins, including SPRK,
which contain Cdc42/Rac interactive binding motifs. Coexpression of
SPRK and activated Cdc42 increases SPRKs activity. SPRKs Cdc42/Rac
interactive binding-like motif contains six of the eight consensus
residues. Using a site-directed mutagenesis approach, we show that SPRK contains a functional Cdc42/Rac interactive binding motif that is
required for SPRKs association with and activation by Cdc42. However,
experiments using a SPRK variant that lacks the COOH-terminal zipper
region/basic stretch suggest that this region may also contribute to
Cdc42 binding. Unlike the PAK family of protein kinases, we find that
the activation of SPRK by Cdc42 cannot be recapitulated in an in
vitro system using purified, recombinant proteins. Comparative
phosphopeptide mapping demonstrates that coexpression of activated
Cdc42 with SPRK alters the in vivo serine/threonine phosphorylation pattern of SPRK suggesting that the mechanism by which
Cdc42 increases SPRKs catalytic activity involves a change in the
in vivo phosphorylation of SPRK. This is, to the best of our knowledge, the first demonstrated example of a Cdc42-mediated change in the in vivo phosphorylation of a protein kinase.
These studies suggest an additional component or cellular environment is required for SPRK activation by Cdc42.
 |
INTRODUCTION |
The vast majority of mammalian protein kinases catalyze the
transfer of the -phosphate of ATP to serine, threonine, or tyrosine residues of their target proteins. Phosphorylation is rendered reversible in vivo by the action of protein phosphatases.
Since phosphorylation is highly regulated in virtually all
physiological processes, it follows that the activities of the protein
kinases, themselves, should be highly regulated. Binding of activating or inhibitory molecules, including lipids, cyclic nucleotides, or
proteins, can modulate the activity of protein kinases. In addition,
post-translational modifications, such as phosphorylation and
proteolysis, can regulate protein kinase activity. These regulatory events may alter the specific activity of a protein kinase or may
change its stability. Finally, access to physiological substrates may
be limited by restricted subcellular localization or translocation of a
protein kinase.
Small GTPases regulate certain protein kinases. For instance, by
binding and recruiting the serine/threonine kinase Raf to the plasma
membrane, GTP-bound, farnesylated Ras contributes to the activation of
Raf, and consequently activates the extracellular-regulated protein
kinase
(ERK)1-mitogen-activated
protein kinase (MAPK) pathway (1). Rho family GTPases, which include
Rho, Rac, and Cdc42, play crucial roles in diverse cellular processes
(2, 3), including cytoskeletal rearrangements (4-6), cell cycle
progression (7), cellular transformation (8-14), and nuclear signaling
(15-20). They can also function as protein kinase activators. One well
characterized target of Cdc42 and Rac is the p21-activated kinase (PAK)
(21-23). The interaction between Cdc42 and the serine/threonine kinase PAK requires the CRIB (Cdc42/Rac interactive binding) motif (26), a
14-16-amino acid sequence containing eight consensus amino acids. The
structural determinants required for GTPase binding and the mechanism
of activation of multiple PAK isoforms have been extensively investigated (21, 24, 25, 32-34). CRIB-dependent
interaction of PAK with GTP-bound Rac/Cdc42 induces PAK
autophosphorylation and activation both in vitro and
in vivo.
Diverse proteins, including the tyrosine kinase, activated
Cdc42HS-associated kinase (ACK) (27), and the non-kinase,
Wiskott-Aldrich Syndrome protein (WASP) (28, 29), also contain CRIB
motifs, suggesting that mechanistically diverse regulatory pathways may share this common structural motif. Likewise, not all protein kinases
which interact with Cdc42 and Rac do so through a CRIB motif. For
instance, both the 70-kDa ribosomal S6 kinase (30) and MAPK kinase
kinase-1 (31), which lack CRIB motifs, have been shown to interact with
GTP-bound Cdc42 and Rac. Furthermore, MAPK kinase kinase-4 contains a
modified CRIB motif whose deletion only partially diminishes binding to
Cdc42 and Rac, indicative of a CRIB-independent GTPase binding
determinant (31). Thus the role of CRIB motifs and the mechanisms by
which many protein kinases are activated by small GTPases remains
largely unexplored.
Src homology 3 domain (SH3)-containing proline-rich protein kinase
(SPRK) (35), also called mixed-lineage kinase-3 (MLK-3) (36), or
protein-tyrosine kinase-1 (37), is a member of the so-called
"mixed-lineage" kinases. SPRK contains a CRIB motif bearing six of
the eight consensus amino acids, as well as other domains that may
mediate protein-protein interactions including an
NH2-terminal SH3 domain, a leucine/isoleucine zipper motif, and a large COOH-terminal region that is rich in serine, threonine, and
proline residues (Fig. 1).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic of SPRK. The
numbers in the diagram represent amino acid number. The
glycine-rich region (amino acids 1-42) is denoted by Gly.
The region containing the zipper motif and the polybasic stretch of
amino acids includes amino acids 400-486. The amino acid sequence
corresponding to this region is shown below with the basic
stretch of amino acids printed in bold letters and the
nonaromatic hydrophobic residues predicted to occupy the d
position in the zipper motifs underlined. The sequence deleted in
SPRK zip (amino acids 430-486) is boxed.
|
|
Upon overexpression in mammalian cell lines SPRK activates c-Jun
NH2-terminal kinase (JNK)/stress-activating protein kinase through phosphorylation and activation of the dual specific kinase, MAPK kinase-4 (MKK-4/SEK1) (38) or MKK-7 (39), and binds the JNK
scaffold proteins, JNK interacting protein (JIP)-1 and JIP-2 (39, 43,
44). In some cell types, SPRK has been reported to activate the MAPK
p38/reactivating kinase via MKK-3/6 (40) as well as ERK (41). SPRK
associates with Rac and Cdc42 in filter binding assays (26) and
coexpression of SPRK, activated Cdc42, and JNK increases SPRK and JNK
activity (42). Whether activation by Cdc42 of the distantly related PAK
and SPRK involves mechanistically analogous processes is unknown. SPRK
is functionally homologous to Raf, and thus mechanistic aspects of
Cdc42-SPRK and Ras-Raf activation may be shared. Here we show that SPRK
contains a functional CRIB motif that is absolutely required for Cdc42
binding to and activation of SPRK. The zipper region and adjacent basic
sequences of SPRK may also contribute to Cdc42 binding. Binding of
Cdc42 to SPRK does not require SPRK catalytic activity. Interestingly, GTP-bound Cdc42 has no effect on the activity of purified,
catalytically active SPRK, suggesting that an additional cellular
component is required for kinase activation. These studies point to an
important distinction between PAK and SPRK in the mode of
GTPase-induced kinase activation. Comparative phosphopeptide mapping
revealed that coexpression of activated Cdc42 with SPRK alters the
in vivo phosphorylation sites on SPRK. This change in
serine/threonine phosphorylation correlates with increased SPRK
activity. These studies represent the first case where a Cdc42-mediated
change in the in vivo phosphorylation sites of a protein
kinase has been documented and provide evidence for the involvement of
in vivo phosphorylation of SPRK for Cdc42-induced
activation. Thus, the Cdc42-mediated activation of SPRK is clearly
distinct from the mechanism previously described for Cdc42-induced
activation of PAK.
 |
EXPERIMENTAL PROCEDURES |
Construction of Mammalian Expression Vectors and
Mutagenesis--
Construction of the cytomegalovirus-based expression
vectors carrying the cDNAs for wild type SPRK
(pRK5-sprk), and for the kinase-defective variant of SPRK
(pRK5-sprk K144A) has been described elsewhere (35).
Expression plasmids encoding NH2-terminal Flag epitope-tagged wild type Cdc42 (pRK5-Nflag.cdc42) and the
constitutively active variant
(pRK5-Nflag.cdc42Val-12) of Cdc42 were kindly
provided by Avi Ashkenazi (Genentech, Inc.).
Variants of SPRK containing point mutations in the CRIB motif were
constructed by a modified recombinant polymerase chain reaction (PCR)
method described in detail elsewhere (45). For each mutation two
different PCRs were performed, one containing a left mutagenesis primer
and a left outside primer, and one containing a right mutagenesis
primer and a right outside primer. The left and right outside
primers used for all mutations were 5'-GATGAGTCATCTGAATCCAGG-3' and
5'-CTGTGGCCTATGGCGTAGCTG-3', respectively. To obtain the three different CRIB mutants the following left and right mutagenesis primers
were used, respectively: SPRK F498A, 5'-GGTGCTTGGCGTCGAGTGGCAT-3' and
5'-ACTCGACGCCAAGCACCGCATC-3'; SPRK H500A, 5'-CTTCAAGGCCCGCATCACCGT-3' and 5'-GGTGATGCGGGCCTTGAAGTCG-3'; SPRK I492A/S493A,
5'-GAAGTCGAGTGGCATGGCGGCACGCTCG-3' and 5'-CGAGCGTGCCGCCATGCCACTCGAC-3'.
The presence of the desired mutation was confirmed by DNA
sequencing using the Sanger method, and the absence of PCR-introduced
errors was verified by automated sequencing.
Deletion of amino acids 430 through 486 of SPRK to yield SPRK zip was
accomplished by digestion of the expression vector pRK5-sprk with BssHII, followed by ligation with T4 DNA ligase. DNA
modifying enzymes were purchased from New England Biolabs or Life
Technologies, Inc.
Expression and Purification of Recombinant SPRK--
An
NcoI-HindIII fragment, containing the full-length
SPRK cDNA, was subcloned from pRK5-sprk into the
pFastBac HTb baculovirus expression vector (Life Technologies, Inc.)
which contains a hexahistidine tag. Recombinant histidine-tagged SPRK
was expressed in Sf21 cells and purified by nickel affinity
chromatography according to the manufacturer's protocol. Fractions
containing histidine-tagged SPRK, as determined by SDS-PAGE followed by
Coomassie Blue staining, were pooled and concentrated using a
Centriprep concentrator (Amicon).
Cell Lines and Transfections--
Human fetal kidney 293 cells
were maintained in Ham's F-12/low glucose Dulbecco's modified
Eagle's media (1:1) (Life Technologies, Inc.) supplemented with 8%
fetal bovine serum (Life Technologies, Inc.), 2 mM
glutamine, and penicillin/streptomycin (Life Technologies, Inc.).
Plasmids (5 µg each for 60-mm dishes; 10 µg each for 100-mm dishes)
were used to transfect 293 cells using the calcium phosphate technique
(46). Cell monolayers were incubated with the DNA precipitate for
4 h, then washed once with PBS (phosphate-buffered saline), and
cultured in the medium described above. After 18 h cells were harvested.
Cell Lysis and Immunoprecipitation--
Cells were washed with
ice-cold PBS and lysed for 5 min on ice by the addition of 1 ml of
lysis buffer (50 mM HEPES (pH 7.5), 150 mM
NaCl, 1.5 mM MgCl2, 2 mM EGTA, 1%
Triton X-100, 10% glycerol, 10 mM sodium fluoride, 1 mM Na4PPi, 100 µM
-glycerophosphate, 1 mM Na3VO4,
2 mM phenylmethylsulfonyl fluoride, and 0.15 units/ml aprotinin). The lysate was clarified by centrifugation for 20 min at
14,000 rpm in an Eppendorf centrifuge at 4 °C. Rabbit polyclonal antiserum was raised against a peptide corresponding to the
COOH-terminal 8 amino acids of SPRK and was purified by Protein
A-Sepharose chromatography. Antibodies against the proteins of interest
were prebound to Protein A-agarose beads (SPRK antiserum (0.25 µg/µl slurry), M2 monoclonal antibody (Kodak IBI) directed against
the Flag epitope (0.45 µg/µl slurry), and JNK C-17 antibody (Santa Cruz Biotechnology) (50 ng/µl slurry)) as described previously (35).
Clarified lysate (300 µl) was incubated with 20 µl of antibody-bound Protein A-agarose for 90 min at 4 °C.
Immunoprecipitates were washed with HNTG buffer (20 mM
HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 10%
glycerol). Immunoprecipitates used for kinase assays were washed three
times with HNTG buffer containing 1 M LiCl, three times
with HNTG buffer, and twice with kinase assay buffer (50 mM
Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM
MnCl2, 10 mM MgCl2, 0.1 mM Na3VO4).
Gel Electrophoresis and Western Blot Analysis--
Lysates and
immunoprecipitates of SPRK and Cdc42 were resolved by SDS-PAGE
according to Laemmli (47). Proteins were transferred to nitrocellulose
and immunoblotted using either SPRK antiserum (1 µg/ml) or M2 Flag
monoclonal antibody (9 µg/ml), followed by the appropriate
horseradish peroxidase-conjugated secondary antibody (Life
Technologies, Inc.). Western blots were developed by chemiluminescence. Multiple exposures of the Western blots were developed, and
densitometry (NIH Image) of unsaturated films was used to determine
relative expression levels. Statistics were compiled using an unpaired Student's t test. A p value smaller than 0.05 was considered statistically significant.
In Vitro Kinase Assays--
Kinase assays were performed in 20 µl of kinase assay buffer containing 50 µM ATP and 5 µCi of [ -32P]ATP (3000 Ci/mmol) (NEN Life Science
Products). For the SPRK kinase assay 10 µg of mixed histones (Roche
Molecular Biochemicals) was used as the substrate and the reaction was
carried out for 30 min at room temperature. Independent experiments
showed that the reaction was linear within this time range. The
reactions were terminated by the addition of an equal volume of 2 × SDS sample buffer (100 mM Tris (pH 6.8), 4% SDS, 20%
glycerol, 0.2% bromphenol blue, 100 mM dithiothreitol, 1%
-mercaptoethanol) containing 50 mM EDTA (pH 8.0).
For the kinase assays involving purified kinases, recombinant SPRK or
PAK-2 (1 and 2 µg, respectively) was incubated in 50 µl of kinase
assay buffer containing 4 µg of GST (glutathione S-transferase)-Cdc42 that had been preloaded with GTP S or
GDP and assay was performed as above. GST-Cdc42 (19 µM)
was preloaded with GTP S or GDP (4 mM) in buffer
containing 50 mM Tris (pH 7.5), 5 mM EDTA, and
1 mM dithiothreitol. The mixture was incubated for 15 min
at 30 °C. The nucleotide loading reaction was quenched by the
addition of 10 mM MgCl2. Purified GST-Cdc42 was
obtained from an Escherichia coli overexpression system; and
purified PAK-2, obtained using the baculovirus expression system, was
kindly provided by Dr. Arie Abo (Onyx Pharmaceuticals) (23).
For the JNK assays, 8 µg of GST-c-Jun was used as the substrate, and
the reaction was carried out for 15 min at room temperature. The
pGEX-c-Jun (1-115) vector was kindly provided by Dr. Ajay Rana (Massachusetts General Hospital, Harvard Medical School, Boston,
MA). GST-c-Jun was expressed in XL-1 Blue E. coli and purified by glutathione-Sepharose chromatography. Following the kinase
assay, proteins were separated by SDS-PAGE. Gels were rinsed in PBS,
dried, and incorporation of radioactivity into kinase or substrates was
determined by PhophorImaging (Molecular Dynamics). To detect JNK
expression, proteins were transferred from an SDS-polyacrylamide gel to
a polyvinylidene difluoride membrane and immunoblotted using the JNK
C-17 antibody (0.5 µg/ml).
MBP Fusion Protein Plasmid Construction--
The predicted
leucine zipper coiled coil domain of the SPRK cDNA encoding amino
acids 386-477 was generated by PCR amplification of the
pRK5-sprk plasmid using the following oligonucleotides: 5'-TCAGAATTCGGATCCGAAATGCCGCGGGACTCCTTC-3' and
5'-ATTGAAGCTTCATGTCCCGCGGCGGCGGCG-3'. The leucine zipper fragment was
cloned into the pMAL-c2 vector (New England Biolabs) at the
EcoRI and HindIII sites, in-frame with the
malE gene, which encodes the monomeric maltose-binding protein (MBP). An MBP control construct was generated using the following linker oligonucleotides encoding a stop codon:
5'-AATTCGGATCCTAATAGCGA-3' and 5'-AGCTTCGCTATTAG GATCCG-3'. The
first of these oligonucleotides was phosphorylated with T4
polynucleotide kinase. The two oligonucleotides were annealed and
ligated into the pMAL-c2 vector which had been digested with
EcoRI and HindIII. Both constructs were confirmed by dideoxy sequencing using Sequenase enzyme (Amersham Pharmacia Biotech).
Expression and Purification of MBP Fusion Proteins--
DH5
derivatives of E. coli containing the recombinant plasmids
were grown at 37 °C in LB medium supplemented with ampicillin (50 µg/ml) and 2% glucose. Protein expression was induced by the addition of 0.3 mM isopropylthiogalactoside for 4 h.
Cells were harvested by centrifugation at 4000 × g for
20 min. Cells were lysed by two passes through a French pressure cell.
MBP proteins were purified by amylose affinity chromatography according
to the manufacturer's protocol. Fractions containing the MBP-zips or
MBP, as determined by SDS-PAGE followed by Coomassie Blue staining, were pooled and concentrated to about 1 mg/ml using a Centriprep concentrator (Amicon).
MBP Pull-down Assay--
One day following transfection of 293 cells with cDNAs encoding SPRK and SPRK zip, the cells were lysed
in 1 ml of lysis buffer as described above. Amylose resin (30 µl) was
incubated with 10 µg of purified MBP or MBP-zips for 60 min at
4 °C, and then washed twice with column buffer (20 mM
Tris (pH 7.4), 200 mM NaCl, 1 mM EDTA).
Cellular lysate from transfected 293 cells (200 µl) was added to the
amylose resin and incubated at 4 °C with mixing for 90 min. After
removal of the lysate, the resin was washed twice with HNTG buffer. The
binding of SPRK or SPRK zip to MBP or MBP-zips was analyzed by
SDS-PAGE followed by Western blotting using the SPRK antiserum.
Coomassie Blue staining verified equal amounts of MBP-containing
proteins in the assays.
Phosphopeptide Mapping--
After a 24-h transfection with
pRK5-sprk in the presence or absence of
pRK5-Nflag.cdc42Val-12, 293 cells were washed
five times with phosphate-free medium (Dulbecco's modified Eagle's
medium supplemented with 10% dialyzed fetal bovine serum (Summit
Biotechnology)), and incubated at 37 °C for 2 h. The cells were
then incubated in phosphate-free medium containing 3 mCi/ml
[32P]orthophosphate (carrier free; NEN Life Science
Products) for 4 h at 37 °C.
Cells were washed five times with ice-cold PBS and then lysed in 1 ml
of lysis buffer. Lysates were clarified by centrifugation for 15 min at
14,000 rpm in an Eppendorf centrifuge at 4 °C. SPRK was
immunoprecipitated with SPRK antiserum as described above. Immunoprecipitated proteins were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. Radiolabeled bands that comigrated with SPRK, as judged by Western blotting, were excised from
the polyvinylidene difluoride membrane. After washing three times with
methanol and three times with water, the radioactive piece of membrane
was blocked with 1 ml of 0.5% polyvinylpyrrolidine-360 (Sigma)
containing 100 mM acetic acid for 30 min at 37 °C, and then washed five times with water. Tryptic digestion was performed with
10 µg of sequencing grade trypsin (Roche Molecular Biochemicals) for
2 h in 200 µl of 50 mM
NH4HCO3 (pH 8.3) at 37 °C. An additional 10 µg of trypsin was added and the digestion mixture was incubated for
an additional 2 h at 37 °C. The membrane was then sonicated for
3 min in 300 µl of water to remove additional tryptic peptides. The
solution containing the released tryptic peptides was concentrated in a
SpeedVac (Savant Instruments).
The peptides were separated on cellulose thin layer chromatography
(TLC) plates (Kodak, 20 × 20 cm) by thin layer electrophoresis (TLE) in the first dimension in pH 1.9 buffer (formic acid (88% w/v)/glacial acetic acid/water, 25:78:897, v/v) at 0 °C and 1000 V
for 30 min, and separated in the second dimension by TLC in phosphochromatography buffer (n-butanol/pyridine/glacial
acetic acid/water, 15:10:3:12, v/v). The radiolabeled phosphopeptides were visualized and quantitated using a PhosphorImager.
Phosphoamino Acid Analysis--
The tryptic peptides were
hydrolyzed in 200 µl of 6 M HCl for 1 h at
100 °C. The phosphoamino acids were concentrated in a SpeedVac.
Unlabeled phosphoamino acid standards (Sigma) and xylene cyanol FF
marker dye (Sigma) were added to each sample. The phosphoamino acids
were separated by one-dimensional TLE in pH 2.5 buffer (66.7% pH 3.5 buffer (glacial acetic acid/pyridine/water, 50:5:945, v/v) and 33.3%
pH 1.9 buffer on cellulose TLC plates at 0 °C and 500 V for 1.5 h. Unlabeled phosphoamino acid standards were visualized by ninhydrin
staining and the 32P-labeled phosphoamino acids derived
from the SPRK peptides were visualized by PhosphorImaging.
 |
RESULTS |
Association of Activated Cdc42 with SPRK Does Not Require SPRK
Kinase Activity--
Recently Hall and co-workers have shown that
several proteins, including SPRK, associate with GTP-bound Cdc42 and
Rac in filter binding assays (26). All of these proteins contain a
14-16-amino acid sequence that includes eight consensus residues,
which has been coined the CRIB motif. The CRIB motif of SPRK contains
six of the eight consensus amino acids (Fig.
2). In this study we examined the
structural requirements and mechanism of Cdc42 binding and activation
of SPRK.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Alignment of CRIB motifs and SPRK CRIB
variants. A, the consensus sequence for the CRIB motif
as defined by Burbelo et al. (27) is shown aligned with the
CRIB motif of MLK-2, WASP, ACK, and SPRK. Amino acid numbers are
indicated to the left and right of each sequence.
Amino acids occupying the consensus residue are indicated in
bold, with those that differ from the consensus
italicized. Absent amino acids are indicated by
periods. The mutations in the engineered CRIB variants of
SPRK are shown with the conserved residue to alanine changes indicated
by bold letters.
|
|
SPRK and Flag epitope-tagged Cdc42 expression vectors were transiently
transfected in 293 cells. To mimic the GTP-bound state of Cdc42 we used
a constitutively active mutant of the GTPase, i.e.
Cdc42Val-12. Cellular lysates from 293 cells were
immunoprecipitated with the Flag antibody and the presence of
associated SPRK was assessed by Western blot analysis with a SPRK
antibody. In these co-immunoprecipitation experiments (Fig.
3A), the constitutively active
form of Cdc42, but not wild type Cdc42, associates with SPRK
(first panel). We have not observed association of SPRK with
the dominant negative variant Cdc42Asn-17, but, in our
hands, expression of this Cdc42 variant has been low. Expression levels
of SPRK and Cdc42 in cellular lysates were determined by Western blot
analysis (Fig. 3A, lower panels). These data indicate that
SPRK preferentially associates with the GTP-bound form of Cdc42.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Expression, coimmunoprecipitation, and SPRK
in vitro kinase activity from cellular lysates
expressing variants of SPRK and Cdc42. Cells were transfected with
expression vectors containing the cDNAs indicated above
each figure. A minus sign indicates that a control empty
vector was transfected. Transient transfections of 293 cells, SDS-PAGE,
co-immunoprecipitation experiments, immunoblotting, and in
vitro kinase assays were performed as described under
"Experimental Procedures." A, coimmunoprecipitation
experiments of SPRK with wild type Cdc42 and the constitutively active
variant Cdc42Val-12. Cdc42 or Cdc42Val-12 was
immunoprecipitated (IP) from cellular lysates using an
antibody directed against the Flag epitope which is appended to the
NH2 termini of the expressed Cdc42 and Cdc42 variant. The
presence of bound SPRK was determined by immunoblotting with a SPRK
antibody (upper panel). The middle and
lower panels show immunoblots of SPRK and Cdc42,
respectively, from cellular lysates. B,
coimmunoprecipitation experiments of SPRK and SPRK K144A with
Cdc42Val-12. Cdc42Val-12 was immunoprecipitated
and the presence of bound SPRK or SPRK K144A was determined by
immunoblotting as described above. The middle and
lower panels show immunoblots of SPRK and Cdc42 from
cellular lysates, respectively. C, in vitro
kinase assay of SPRK and SPRK variants. SPRK was immunoprecipitated and
subjected to an in vitro kinase assay using histones as a
substrate. To eliminate contaminating (non-SPRK) kinase activity in the
immune complex in vitro kinase assay, SPRK
immunoprecipitates were stringently washed. The top panel
shows an autoradiogram with bands corresponding to SPRK
autophosphorylation and histone phosphorylation indicated by
arrows. The middle and lower panels
show immunoblots of SPRK and Cdc42Val-12 from cellular
lysates, respectively. The kinase assay shown in C is
representative of five independent experiments.
|
|
SPRK can autophosphorylate in vitro (35). Although SPRKs
postulated site of interaction with Cdc42 is not within the catalytic domain, it is plausible that either SPRK autophosphorylation or SPRK
phosphorylation of another interacting molecule might modulate the
Cdc42-SPRK interaction. To examine whether SPRKs catalytic activity
effects its ability to bind to Cdc42, the kinase-defective SPRK variant
(SPRK K144A) was tested for its ability to associate with
Cdc42Val-12. The SPRK K144A variant shows no
autophosphorylation in an in vitro kinase assay (35).
Co-transfection and co-immunoprecipitation experiments with active and
inactive SPRK, and Cdc42Val-12, demonstrate that
constitutively active Cdc42 associates equally well with wild type SPRK
and the kinase-defective variant SPRK K144A (Fig. 3B, upper
panel). This indicates that SPRKs catalytic activity is not
required for its association with Cdc42. The retarded mobility of wild
type SPRK, as compared with that of inactive SPRK, suggests a more
highly phosphorylated form of SPRK that is likely due, at least in
part, to autophosphorylation (Fig. 3B, upper and
middle panels).
To determine whether association with Cdc42 effects SPRKs catalytic
activity, an in vitro kinase assay for SPRK was developed. While its kinase domain shares overall sequence similarity with both
serine/threonine and tyrosine kinases, SPRK shows high amino acid
sequence identity with the serine/threonine kinase B-Raf in a small
region of subdomain VIb and VIII that is important for substrate
specificity and catalytic activity (48). In addition, both Raf and SPRK
appear to function as MKKKs leading primarily to the activation of ERK
and JNK, respectively. Since histones are commonly employed as
exogenous substrates for Raf in in vitro kinase assays (49,
50), a mixture of histones was tested as an exogenous substrate for
SPRK. SPRK, immunoprecipitated from cellular lysates of transiently
transfected 293 cells, exhibits basal autophosphorylation as well as
phosphorylation of the histones H3 and H4 (Fig. 3B). In
contrast, the kinase-defective SPRK shows no autophosphorylation or
histone phosphorylation, indicating that the phosphorylation events
observed in these assays are attributable to SPRK, rather than to
contaminating kinases.
The expression of Cdc42Val-12 in transiently transfected
293 cells increases the autophosphorylation activity as well as the
substrate phosphorylation activity of SPRK about 3-5-fold (Fig.
3C). No background phosphorylation is observed with the
kinase-defective SPRK variant in the presence or absence of
Cdc42Val-12. Interestingly, under these in vitro
kinase assay conditions, we do not detect Cdc42 associated with SPRK by
Western blotting (data not shown).
SPRKs CRIB Motif Is Necessary for Association with Cdc42 and for
Cdc42-induced Activation of SPRK--
To test whether SPRKs potential
CRIB motif actually functions in the binding of Cdc42 we took a
site-directed mutagenesis approach. Three different SPRK variants were
generated by mutating conserved amino acids in the CRIB motif to
alanine residues: SPRK F498A, SPRK H500A, and SPRK I492A/S493A (Fig.
2). While we cannot absolutely rule out the possibility that
introduction of these mutations might alter SPRKs conformation, the
expression levels of the SPRK CRIB mutants in transient transfections
of 293 cells are at least as high as that of wild type SPRK (Fig.
4A), suggesting that these
variants are stable. The CRIB variants were coexpressed with
Cdc42Val-12 in 293 cells and the cellular lysates were
subjected to co-immunoprecipitation experiments. While wild type SPRK
associates with Cdc42Val-12, none of the SPRK CRIB mutants
detectably associates with the activated GTPase (Fig.
4A).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of mutations in the CRIB motif on
Cdc42Val-12 binding and activation of SPRK.
A, coimmunoprecipitation experiments of SPRK and SPRK CRIB
variants with Cdc42Val-12. The presence of the bound SPRK
or SPRK CRIB variant was assessed by immunoblotting with a SPRK
antibody as described previously. The middle and lower
panels show immunoblots of SPRK and Cdc42Val-12 from
cellular lysates, respectively. B, in vitro
kinase assays of SPRK and SPRK I492A/S493A. SPRK autophosphorylation
was quantified by PhosphorImaging and normalized to relative SPRK
expression levels as described under "Experimental Procedures." The
mean ± S.E. of three independent experiments are shown.
C, in vitro kinase assays of SPRK and SPRK
I492A/S493A. Histone phosphorylation was quantified and normalized to
relative SPRK expression levels as described above. The mean ± S.E. of three independent experiments are shown.
|
|
If Cdc42-induced activation of SPRK is mediated through its interaction
with SPRKs CRIB motif, one would expect that the SPRK CRIB mutants
should exhibit a defect in Cdc42-induced activation. Accordingly, cells
were transiently transfected with cDNAs encoding wild type SPRK or
SPRK I492A/S493A, in the presence or absence of
Cdc42Val-12. The activity of the immunoprecipitated SPRK or
SPRK CRIB mutant was measured in an in vitro kinase assay.
In the absence of Cdc42Val-12, both wild type SPRK and the
SPRK CRIB variant show similar levels of autophosphorylation and
substrate phosphorylation (Fig. 4, B and C). In
the absence of Cdc42Val-12, the differences in the
activities of SPRK and the SPRK CRIB variants were not statistically
significant. This further supports the idea that the mutations in the
CRIB motif do not grossly perturb SPRKs structure or inherent catalytic
activity. However, both autophosphorylation and substrate
phosphorylation of the CRIB variant is markedly lower (3-fold) than
that of wild type SPRK, when each is coexpressed with the activated
GTPase (Fig. 4, B and C). The small increase in
the catalytic activity of the SPRK CRIB mutant when activated Cdc42 is
coexpressed may be due to Cdc42-activated endogenous SPRK.
Alternatively there may be residual binding of the CRIB variant to
activated Cdc42 in vivo, which we do not detect in our
in vitro co-immunoprecipitation assay. Taken together these
results demonstrate that SPRK does contain a functional CRIB motif, and
that Cdc42-induced activation of SPRK is mediated via association with
this CRIB motif.
Effects of Deleting the COOH-terminal Portion of SPRKs Zipper
Domain--
In WASP (51), PAK (32, 52), and ACK (27) the CRIB motif is
necessary but not sufficient for GTPase binding. Outside of the CRIB
motif SPRK shares no sequence similarity with the minimal
GTPase-binding domains that have been defined for these proteins.
Instead, SPRK contains two closely spaced leucine/isoleucine zipper
motifs spanning amino acids 400-462, COOH-terminal to the CRIB motif
(Fig. 1). Considering the close vicinity in linear sequence of the
zippers and the CRIB motif we asked whether the zipper motif might
contribute to the binding of SPRK to Cdc42Val-12.
Accordingly, a variant of SPRK, SPRK zip, which lacks amino acids
430-486, as shown in Fig. 1, was constructed. This deletion removes
the second half of the zipper region as well as 22 COOH-terminal amino
acids which includes a short basic region, but leaves the entire CRIB
motif intact.
SPRK zip is expressed in transiently transfected 293 cells at levels
comparable to that of wild type SPRK (Fig.
5A). The ability of
Cdc42Val-12 to associate with SPRK zip was tested in
co-immunoprecipitation experiments with cellular lysates harvested from
transiently transfected 293 cells. The deletion of the second
zipper/basic stretch greatly diminishes the ability of SPRK to bind to
Cdc42Val-12, despite the presence of the complete CRIB
motif (Fig. 5A). Based on these and our previous results,
both the CRIB motif and the second half of the zipper region and a
stretch of basic amino acids may contribute to Cdc42 binding.
Alternatively, the COOH-terminal zipper/basic stretch may not directly
interact with Cdc42, but may be required for the proper presentation
and binding of the CRIB motif to the GTPase.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of partial deletion of the
zipper/basic stretch of SPRK on Cdc42Val-12 binding and
activation of SPRK. A, coimmunoprecipitation
experiments of SPRK and SPRK zip with Cdc42Val-12. The
presence of bound SPRK or SPRK zip was assessed by immunoblotting
with a SPRK antibody as described previously. The middle and
lower panels show immunoblots of SPRK variants and
Cdc42Val-12 from cellular lysates, respectively.
B, in vitro kinase assays of SPRK and SPRK zip
using histones as a substrate. The top panel shows an
autoradiogram with bands corresponding to phosphorylated histones
indicated by arrows. The middle and lower
panels show immunoblots of SPRK and Cdc42Val-12 from
cellular lysates, respectively. C, quantitation of in
vitro kinase assays of SPRK and SPRK zip. SPRK
autophosphorylation was quantified by PhosphorImaging and normalized to
SPRK expression levels as described under "Experimental
Procedures." The mean ± S.E. of three independent experiments
are shown. D, quantitation of in vitro kinase
assays of SPRK and SPRK zip. Histone phosphorylation was quantified
by PhosphorImaging and normalized to SPRK expression levels as
described under "Experimental Procedures." The mean ± S.E. of
three independent experiments are shown.
|
|
SPRK zip has approximately 70% of the basal autophosphorylation
activity of wild type SPRK (Fig. 5, B and C).
However, in contrast to wild type SPRK, there is no Cdc42-induced
increase in autophosphorylation of SPRK zip, consistent with the
finding that SPRK zip binds Cdc42Val-12 only very weakly.
In an in vitro kinase assay, SPRK zip expressed with or
without Cdc42Val-12 (Fig. 5, B and D)
lacks the ability to phosphorylate histones. To address whether the
lack of histone phosphorylation might be due to some unique feature of
histones we performed the same experiment with myelin basic protein as
a substrate and obtained the analogous results (data not shown). These
data suggest that the zipper domain/basic stretch may be fundamentally
required for substrate phosphorylation.
SPRK zip Fails to Activate JNK--
SPRK has been identified as
an upstream activator of the JNK/stress-activating protein kinase
pathway (38, 40, 42). JNK activity was measured after
immunoprecipitation of endogenous JNK from cellular lysates of
transiently transfected 293 cells in an immune complex in
vitro kinase assay using GST-c-Jun as the substrate.
Overexpression of SPRK in 293 cells leads to a 5-fold increase in JNK
activity over the basal activity in vector control-transfected cells
(Fig. 6, A and B).
Transient expression of Cdc42Val-12 increases JNK activity
some 2-3-fold. Although coexpression of SPRK and
Cdc42Val-12 increases SPRK catalytic activity, as measured
in an in vitro kinase assay, the observed SPRK-induced JNK
activation with coexpressed Cdc42Val-12 over that of SPRK
alone does not reach statistical significance. A likely explanation for
this finding is that the activity of overexpressed SPRK alone is
sufficient to maximally activate the endogenous JNK in 293 cells.
SPRK zip is unable to phosphorylate an exogenous substrate in an
in vitro kinase assay, and, indeed, we have found that it
completely lacks the ability to activate the JNK pathway (Fig. 6,
A and B). Thus, it appears that the zipper motif
is critical for substrate phosphorylation by SPRK both in vitro and in vivo.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of SPRK zip on
JNK activity. A, endogenous JNK-1 was
immunoprecipitated from cellular lysates that had been transiently
transfected with cDNAs encoding the specified SPRK and/or Cdc42
variants. An in vitro immune complex assay for JNK activity
was performed using GST-c-Jun as a substrate. The uppermost
panel shows an autoradiogram with bands corresponding to GST-c-Jun
indicated by an arrow. The second panel shows a
JNK immunoblot of the same immunoprecipitated samples from the in
vitro kinase assay. The third panel shows a SPRK
immunoblot of cellular lysates. The lowest panel shows an
immunoblot for Cdc42 from cellular lysates. B, quantitation
of in vitro kinase assays of JNK. GST-c-Jun phosphorylation
was measured by PhosphorImaging and normalized to SPRK expression
levels as described under "Experimental Procedures." The mean ± S.E. for fold-increase in GST-c-Jun phosphorylation in three
independent experiments are graphed.
|
|
The Leucine Zipper Domain Is Sufficient for SPRK
Oligomerization--
Despite its substantial autophosphorylation
activity, SPRK zip fails to activate JNK. To characterize the
oligomerization properties of SPRK zip, we engineered a cDNA
construct encoding amino acids 386-477 of SPRK fused to the coding
sequence of the monomeric MBP of E. coli, designated
MBP-zips, and tested purified MBP and MBP-zips for their ability to
associate with full-length SPRK and SPRK zip. As shown in Fig.
7A, full-length SPRK binds MBP-zips but not MBP, as judged by immunoblotting. Furthermore, SPRK zip fails to bind either MBP-zips or MBP. Equal amounts of MBP
or MBP-zips in the assays were verified by Coomassie Blue staining of a duplicate gel (Fig. 7B). Western blotting of
cellular lysates using a SPRK antibody shown in Fig. 7C,
reveals that full-length SPRK and SPRK zip were expressed at similar
levels. These data provide direct evidence that the leucine
zipper/basic stretch of SPRK is capable of protein-protein interactions
and is sufficient to mediate SPRK homo-oligomerization.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Assay for association of the zipper/basic
stretch of SPRK with SPRK and SPRK zip in
vitro. Lysates from 293 cells expressing SPRK or
SPRK zip were incubated with amylose resin to which purified MBP or
MBP-zips had been prebound. A, after washing of the resin,
the presence of bound SPRK or SPRK zip was assessed by immunoblotting
with the SPRK antibody. B, equal loading of MBP and MBP-zips
on the amylose resin was confirmed by Coomassie staining. C,
expression of SPRK and SPRK zip was assessed by immunoblotting of
cellular lysates with a SPRK antibody.
|
|
Activated Cdc42 Fails to Activate SPRK in Vitro--
The small
GTPases Rac and Cdc42 can stimulate the autophosphorylation activity of
the CRIB-containing serine/threonine kinase PAK-2 in vitro
(23). To determine whether Cdc42-induced activation of SPRK can be
recapitulated in a completely in vitro system, hexahistidine
NH2-terminal tagged SPRK was expressed using the baculovirus system, and purified by metal-chelate chromatography. GST-Cdc42 was expressed in and purified from E. coli. The
purified SPRK is catalytically active as judged by its basal
autophosphorylation activity. GTP S- or GDP-loaded GST-Cdc42 was
incubated with purified SPRK or PAK-2 in an in vitro kinase
assay (Fig. 8B). While
GTP S-loaded Cdc42 activates purified PAK-2, it fails to activate
purified SPRK. Likewise, SPRK immunoprecipitated from transfected 293 cells cannot be activated in vitro by the addition of
GTP S-loaded Cdc42 (Fig. 8A). These data support the
requirement of a cellular context or coactivator for SPRK activation by
Cdc42.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8.
In vitro kinase assays using
purified Cdc42. A, SPRK was immunoprecipitated from
cellular lysates that had been transiently transfected with cDNA
encoding SPRK and was incubated in an in vitro kinase assay
in the presence of 4 µg of GST-Cdc42 preloaded with either GTP S or
GDP. The top panel shows an autoradiogram with bands
corresponding to SPRK autophosphorylation indicated by
arrows. The lower panel show an immunoblot of
SPRK from cellular lysates. B, purified SPRK and PAK-2 (1 and 2 µg, respectively) were incubated in an in vitro
kinase assay in the presence of 4 µg of GST-Cdc42 preloaded with
either GTP S or GDP. Shown is an autoradiogram with bands
corresponding to SPRK autophosphorylation and PAK-2 autophosphorylation
indicated by arrows.
|
|
Cdc42 Alters the in Vivo Phosphorylation Pattern of SPRK--
As
described above, co-immunoprecipitation experiments and in
vitro kinase assays show that Cdc42Val-12 when
coexpressed with SPRK can associate with SPRK and modulate its
catalytic activity. However, purified, activated Cdc42 cannot stimulate
the autophosphorylation of SPRK in vitro. In order to determine if the presence of activated Cdc42 alters SPRK
phosphorylation in vivo, two-dimensional phosphopeptide
analysis of SPRK labeled in vivo, in the absence and
presence of Cdc42Val-12, was performed.
The net incorporation of radiolabel into SPRK increased approximately
3-fold when SPRK was coexpressed with Cdc42Val-12.
Two-dimensional TLE/TLC revealed that while the basic pattern of
phosphopeptides from the two samples is similar (Fig.
9A), there are notable
differences. The major changes are observed in the triangular cluster
of phosphopeptides b, c, and d.
Phosphopeptide a predominates in both samples.
Phosphopeptides b and c are detected in the
triangular cluster of the SPRK map, but are low in abundance relative
to peptide a. In the corresponding map of SPRK that had been
expressed in the presence of Cdc42Val-12, however,
phosphopeptide b is not detected. Instead, phosphopeptide c is the prominent phosphopeptide in the triangular cluster,
with 70% of the radioactivity of phosphopeptide a (Fig.
9B). Furthermore, phosphopeptide d, nearly
undetectable in the map of SPRK, appears at high levels in the map of
SPRK expressed with Cdc42Val-12. For comparison, the level
of another peptide (x) relative to peptide a is
essentially constant in both maps. The labeling and mapping from three
independent experiments yielded the same results. These data indicate
that the presence of activated Cdc42 changes the in vivo
phosphorylation state of SPRK, which correlates with an increase in
SPRK catalytic activity. Phosphoamino acid analysis of the pooled
tryptic phosphopeptides (Fig. 9C) reveals predominantly serine phosphorylation, some threonine phosphorylation, and no tyrosine
phosphorylation. The ratios of phosphoserine to phosphothreonine in the
two samples are not substantially different.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 9.
Phosphopeptide mapping and
phosphoamino acid analysis of tryptic peptides derived from in
vivo phosphorylated SPRK. See "Experimental
Procedures" for detail. A, two-dimensional phosphopeptide
mapping of 32P-labeled SPRK from 293 cells transfected with
expression vectors for SPRK (top) or for SPRK and
Cdc42Val-12 (bottom). SPRK was immunopurified
from cellular lysates, blotted onto a polyvinylidene difluoride
membrane, and subjected to partial trypsin digestion. Equal amounts of
radioactivity, as determined by Cerenkov counting of the resultant
tryptic peptides, were analyzed by TLE in the first dimension and TLC
in the second dimension. The direction of the electrophoresis and
chromatography are indicated by long arrows. Phosphopeptides
were visualized by PhosphorImaging. The phosphopeptides of interest are
alphabetically labeled. Shown is a representative map from three
independent experiments. B, the percent radioactivity of the
indicated phosphopeptides compared with phosphopeptide a.
Calculated as: [(volume background)phosphopeptide]/[(volume background)phosphopeptide
a] × 100, using Image Quant software (Molecular Dynamics).
C, phosphoamino acid analysis of in vivo
32P-labeled SPRK. Phosphoamino acids derived from the SPRK
tryptic peptides in A were separated by TLE and visualized
by PhosphorImaging. The third lane (Stds) shows the positions of
phosphoamino acid standards. The position of free inorganic phosphate
(Pi) is also indicated.
|
|
 |
DISCUSSION |
Small GTPases of the Ras superfamily have been shown to regulate
protein kinases. PAK has emerged as the paradigm CRIB-containing serine/threonine kinase that is activated by GTP-bound Cdc42 and/or Rac. The PAKs play roles in diverse processes, including apoptosis, modulation of actin cytoskeleton, gene transcription, and cell cycle
(53). SPRK is a member of the so-called mixed-lineage kinases. Except
for the presence of a loosely conserved CRIB motif, SPRK differs
dramatically from the PAKs, both structurally and functionally. While
the mammalian PAK-1, -2, and -3 share 95% sequence similarity in their
catalytic domains, SPRKs catalytic domain is just 20% similar to those
of the mammalian PAKs. The CRIB motif of the PAKs is found
NH2-terminal to the catalytic domain, whereas SPRKs CRIB
motif is COOH-terminal to the catalytic domain. Flanking SPRKs
catalytic domain is an NH2-terminal SH3 domain and a
COOH-terminal leucine zipper motif, both lacking in the PAKs. The only
well established function thus far ascribed to SPRK is as an MKKK in
the activation of the JNK pathway. Because the MLKs are so different
from the PAKS, it is important to determine whether the structural
features of their binding to and the mechanisms of activation by Cdc42
and/or Rac also differ from that of the PAKs.
Whereas the three mammalian PAK isoforms contain perfect consensus CRIB
motifs, as defined by Burbelo et al. (26), SPRKs CRIB motif
contains only six of the eight consensus residues (Fig. 2). We show
that mutations in conserved residues of SPRKs CRIB motif disrupt the
ability of the Cdc42 to bind to and activate SPRK, indicating that SPRK
does indeed contain a functional CRIB motif. WASP and ACK, two other
proteins whose CRIB-dependent binding to Cdc42 has been
well established, also contain less than perfect CRIB motifs (Fig. 2),
with WASP (28, 29), and ACK (27) containing 7 of the 8 consensus
residues, and 6 of the 8 consensus residues, respectively. It may well
be that the CRIB consensus motif is biased toward PAK, due to the large
number of PAK isoforms that have been identified.
SPRK and the closely related MLK-2 lack the second of the two conserved
histidine residues of the consensus CRIB motif (Fig. 2). We show here
that mutation of the first conserved histidine in SPRK to an alanine
residue (H500A) disrupts binding to Cdc42. The fact that both SPRK (26)
and MLK-2 (26, 54) have been demonstrated to bind Cdc42 may indicate
that the second of the two conserved histidines in the consensus CRIB
motif in other CRIB-containing proteins is not required for binding to
Cdc42. Further support for this notion is provided by the finding that the conserved Asp38 in Cdc42 interacts primarily with the
first of the two conserved histidine residues (His520) in
ACK (55). In addition, mutation of the first of the two conserved
histidine residues in N-WASP to aspartate (H208D) decreases the
in vitro binding affinity for Cdc42 and Rac, as well as the activity of N-WASP in vivo and in vitro (56). The
regions outside of the CRIB motifs of ACK and WASP exhibit low sequence
similarity, and, perhaps not surprisingly, low structural similarity
when bound to Cdc42 (55, 57). It is likely that the GTPase-binding domain of SPRK, with the exception of the CRIB motif, will differ structurally from those of both WASP and ACK.
Because of the proximity of SPRKs zipper and CRIB motifs in linear
sequence, and because sequences flanking the CRIB motif in other
proteins contribute to Cdc42/Rac binding, we tested whether deletion of
the COOH-terminal half of the zipper motif effects Cdc42 binding. The
binding of SPRK zip (Fig. 1), which contains an intact CRIB motif, to
activated Cdc42 is reduced more than 10-fold, suggesting that, in
addition to SPRKs CRIB motif, the zipper domain or the following short
basic region of SPRK may contribute to Cdc42 binding. Interestingly,
the basal autophosphorylation activity of SPRK zip is about 70% that
of wild type SPRK. This may indicate some intramolecular
autophosphorylation activity. Alternatively, SPRK zip may
homo-oligomerize and undergo intermolecular autophosphorylation. Leung
and Lassam (58) recently reported a very large reduction in
GST-SPRK/MLK-3 autophosphorylation activity in vitro upon
deleting the entire zipper region, but leaving the basic stretch intact.
Recent site-directed mutagenesis studies indicate that the
serine/threonine kinase PAK contains a basic stretch consisting of
three contiguous lysine residues upstream of the CRIB motif, whose
charge is important for binding to Rac1 and Rac2, and whose presence is
required for efficient PAK-1 activation by Rac1, Rac2, and Cdc42 (33).
SPRK contains four contiguous arginine residues between the zipper
domain and the CRIB motif. These basic amino acids are deleted in the
SPRK zip variant, which exhibits greatly reduced binding to activated
Cdc42. Thus, it is plausible that the arginine tract in SPRK may
contribute to Cdc42 binding or activation of SPRK. Currently we are
defining a minimal Cdc42-binding domain of SPRK and are assessing the
relative contributions of various amino acids within this domain to
Cdc42 binding and Cdc42-induced SPRK activation.
We show that SPRK and activated Cdc42 can be co-immunoprecipitated from
cellular lysates. However, under the conditions of our in
vitro kinase assay, which clearly show a Cdc42-induced increase in
SPRK autophosphorylation and histone phosphorylation, Cdc42 is not
detected. Possibly once SPRK is activated by Cdc42, SPRK has a reduced
affinity for the GTPase as has been demonstrated with PAK-2 (21).
Furthermore, the sites of in vitro autophosphorylation of
SPRK expressed with and without Cdc42, and isolated from mammalian cells, are essentially identical as judged by mapping of tryptic phosphopeptides (data not shown). The mechanism by which the highly conserved PAK family members (PAK-1, -2, and -3) are activated by Rac
and Cdc42 has been well studied. Increased autophosphorylation activity
is observed upon incubation of purified activated Cdc42 with purified
PAK. In contrast to PAK, purified, catalytically active SPRK cannot be
further activated in vitro by the addition of GTP-bound
Cdc42. These data are consistent with a catalytic model in which Cdc42
activates SPRK in vivo, but is not required to maintain SPRK
in its activated state. We therefore decided to assess whether Cdc42
induces differential phosphorylation of SPRK in vivo.
Phosphoamino acid analysis of in vivo labeled SPRK revealed
serine and threonine, but no tyrosine, phosphorylation. Two-dimensional tryptic phosphopeptide mapping studies of in vivo labeled
SPRK, expressed with or without constitutively active Cdc42, showed similar phosphopeptide maps, with major differences observed in a
triangular cluster of phosphopeptides b, c, and
d (Fig. 9A). In the map of SPRK alone,
phosphopeptides b and c are present, but at low
levels. When activated Cdc42 is coexpressed with SPRK, phosphopeptide
b is not detected and phosphopeptides c and
d appear at high levels. Since the change in in
vivo phosphorylation of SPRK with Cdc42 correlates with increased
SPRK activity, it is likely that phosphopeptides c and
d contain activating phosphorylation sites. Phosphopeptides
c and d may be distinct phosphopeptides. However,
since their chromatographic mobilities are essentially identical, it is
also possible that phosphopeptides c and d result from differential trypsin digestion. Phosphopeptides b and
c lie on a diagonal which slopes toward the anode,
characteristic of peptides that are phosphoisomers. Upon
phosphorylation, the negative charge and polar nature of the added
phosphate group reduces a peptides mobility in both the electrophoretic
and chromatographic dimensions (59). Therefore, phosphopeptide
c may differ from phosphopeptide b by the
addition of a phosphate group(s). This is consistent with the
observation that when activated Cdc42 is coexpressed with SPRK,
phosphopeptide c emerges while phosphopeptide b disappears.
Cdc42 may induce differential SPRK autophosphorylation in
vivo or, alternatively, another SPRK-activating kinase may be
responsible for the in vivo change in SPRK phosphorylation.
Because Cdc42 is geranylgeranylated (60) and has been localized to
cellular membranes (61, 62, 63) as well as to cytoskeletal elements (64), it is possible that Cdc42 recruits SPRK to the vicinity of an
activating kinase. SPRK and the serine/threonine kinase Raf both appear
to function as MKKKs, activating the JNK and ERK pathways,
respectively. The idea that Cdc42 may recruit SPRK to an activating
kinase is reminiscent of the proposed mechanism by which the small
GTPase Ras activates Raf. Analogous to our findings with Cdc42 and
SPRK, the addition of purified, activated Ras to Raf in
vitro is not sufficient for full activation of Raf. However,
appending a membrane targeting motif to the COOH terminus of Raf causes
Raf translocation and activation in the absence of activated Ras (1).
It has been recently shown that PAK-3 phosphorylates Raf in
vivo and in vitro leading to an increase in Raf
activity (65), although it has yet to be determined whether this event
requires Raf translocation. In yeast, the PAK homolog STE20 functions
as an MKKK in the activation of a yeast MAPK pathway. By analogy, potential SPRK-activating kinases may include PAK-related kinases (53)
such as hematopoietic protein kinase-1. In coexpression studies
hematopoietic protein kinase-1 binds to SPRKs SH3 domain and
phosphorylates SPRK, but the effect on SPRK activity is not reported
(66). Interestingly, unlike PAK-1, -2, and -3, hematopoietic protein
kinase-1 lacks a CRIB motif. Our finding that catalytically active SPRK
cannot be further activated in vitro by GTP-bound Cdc42
suggests that the GTPase activates SPRK differently than the PAKs.
Whereas the PAKs can be activated in vitro by interaction with unprenylated GTP-bound Cdc42, the activation of SPRK by Cdc42 appears to require prenylation of Cdc42, the cellular environment, or
an as yet unidentified cellular component. Our data supports a model in
which the in vivo CRIB-dependent interaction of
SPRK and Cdc42 either allows SPRK to adopt a conformation that leads to
autophosphorylation or recruits SPRK to the vicinity of a
serine/threonine kinase that phosphorylates and activates SPRK.
Determination of the precise sites of Cdc42-induced phosphorylation of
SPRK, coupled with subcellular localization studies, should shed
further light on the detailed mechanism of SPRK activation by Cdc42.
 |
ACKNOWLEDGEMENTS |
We are grateful to Hua Zhang for expression
and purification of recombinant GST-Cdc42; Arie Abo (Onyx
Pharmaceuticals) for providing purified PAK-2; and Avi Ashkenazi
(Genentech, Inc.) for mammalian Cdc42 expression vectors. We thank
Donald B. Jump and Walter J. Esselman for valuable discussions and
critical reading of the manuscript. We appreciate the support and
reagents from Paul Godowski (Genentech, Inc.).
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant CA76306.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Contributed equally to the results of this work.
Supported by the National Science Foundation-REU program at
Michigan State University.
**
To whom correspondence should be addressed: Depts. of Physiology
and Biochemistry, 108 Giltner Hall, Michigan State University, East
Lansing, MI 48824. Tel.: 517-355-6475; Fax: 517-355-5125, E-mail:
gallo@psl.msu.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
ERK, extracellular
regulated protein kinase;
MAPK, mitogen-activated protein kinase;
PAK, p21-activated kinase;
CRIB, Cdc42/Rac-interactive binding;
ACK, activated Cdc42HS-associated kinase;
WASP, Wiskott-Aldrich Syndrome
protein;
SPRK, SH3 domain-containing proline-rich kinase;
SH3, Src-homology 3;
MLK, mixed-lineage kinase;
JNK, c-Jun
NH2-terminal kinase;
MKK, MAPK kinase;
JIP, JNK interacting
protein;
PCR, polymerase chain reaction;
PBS, phosphate-buffered
saline;
PAGE, polyacrylamide gel electrophoresis;
GST, glutathione
S-transferase;
MBP, maltose-binding protein;
GTP S, guanosine 5'-3-O-(thio)triphosphate.
 |
REFERENCES |
| 1.
|
Stokoe, D.,
Macdonald, S. G.,
Cadwallader, K.,
Symons, M.,
and Hancock, J. F.
(1994)
Science
264,
1463-1467[Abstract/Free Full Text]
|
| 2.
|
Van Aelst, L.,
and D'Souza-Schorey, C.
(1997)
Genes Dev.
11,
2295-2322[Free Full Text]
|
| 3.
|
Hall, A.
(1998)
Science
279,
509-514[Abstract/Free Full Text]
|
| 4.
|
Nobes, C. D.,
and Hall, A.
(1995)
Cell
81,
53-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kozma, R.,
Ahmed, S.,
Best, A.,
and Lim, L.
(1995)
Mol. Cell. Biol.
15,
1942-1952[Abstract]
|
| 6.
|
Ridley, A. J.,
Paterson, H. F.,
Johnston, C. L.,
Diekmann, D.,
and Hall, A.
(1992)
Cell
70,
401-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Olson, M. F.,
Ashworth, A.,
and Hall, A.
(1995)
Science
269,
1270-1272[Abstract/Free Full Text]
|
| 8.
|
Qiu, R-G.,
Chen, J.,
Kirn, D.,
McCormick, F.,
and Symons, M.
(1995)
Nature
374,
457-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Khosravi-Far, R.,
Solski, P. A.,
Clark, G. J.,
Kinch, M. S.,
and Der, C. J.
(1995)
Mol. Cell. Biol.
11,
6643-6453
|
| 10.
|
Qiu, R.-G.,
Abo, A.,
McCormick, F.,
and Symons, M.
(1997)
Mol. Cell. Biol.
17,
3449-3458[Abstract]
|
| 11.
|
Tang, Y.,
Chen, Z.,
Ambrose, D.,
Liu, J.,
Gibbs, J. B.,
Chernoff, J.,
and Field, J.
(1997)
Mol. Cell. Biol.
17,
4454-4464[Abstract]
|
| 12.
|
Wu, W. J.,
Lin, R.,
Cerione, R. A.,
and Manor, D.
(1998)
J. Biol. Chem.
273,
16655-16658[Abstract/Free Full Text]
|
| 13.
|
Whitehead, I. P.,
Abe, K.,
Gorski, J. L.,
and Der, C. J.
(1998)
Mol. Cell. Biol.
18,
4689-4697[Abstract/Free Full Text]
|
| 14.
|
Tang, Y., Yu, J.,
and Field, J.
(1999)
Mol. Cell. Biol.
19,
1881-1891[Abstract/Free Full Text]
|
| 15.
|
Zhang, S.,
Han, J.,
Sells, M. A.,
Chernoff, J.,
Knaus, U. G.,
Ulevitch, R. J.,
and Bokoch, G. M.
(1995)
J. Biol. Chem.
270,
23934-23936[Abstract/Free Full Text]
|
| 16.
|
Coso, O. A.,
Chiariello, M., Yu, J.-C.,
Teramoto, H.,
Crespo, P.,
Xu, N.,
Miki, T.,
and Gutkind, J. S.
(1995)
Cell
81,
1137-1146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Bagrodia, S.,
Dérijard, B.,
Davis, R. J.,
and Cerione, R. A.
(1995)
J. Biol. Chem.
270,
27995-27998[Abstract/Free Full Text]
|
| 18.
|
Brown, J. L.,
Stowers, L.,
Baer, M.,
Trejo, J.,
Coughlin, S.,
and Chant, J.
(1996)
Curr. Biol.
6,
598-605[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Minden, A.,
Lin, A.,
Claret, F.-X.,
Abo, A.,
and Karin, M.
(1995)
Cell
81,
1147-1157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Hill, C. S.,
Wynne, J.,
and Treisman, R.
(1995)
Cell
81,
1159-1170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Manser, E.,
Leung, T.,
Salihuddin, H.,
Zhao, Z.,
and Lim, L.
(1994)
Nature
367,
40-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Bagrodia, S.,
Taylor, S. J.,
Creasy, C. L.,
Chernoff, J.,
and Cerione, R. A.
(1995)
J. Biol. Chem.
270,
22731-22737[Abstract/Free Full Text]
|
| 23.
|
Martin, G. A.,
Bollag, G.,
McCormick, F.,
and Abo, A.
(1995)
EMBO J.
14,
1970-1978[Medline]
[Order article via Infotrieve]
|
| 24.
|
Manser, E.,
Huang, H.-Y.,
Loo, T.-H.,
Chen, X.-Q.,
Dong, J.-M.,
Leung, T.,
and Lim, L.
(1997)
Mol. Cell. Biol.
17,
1129-1143[Abstract]
|
| 25.
|
Gatti, A.,
Huang, Z.,
Tuazon, P. T.,
and Traugh, J. A.
(1999)
J. Biol. Chem.
274,
8022-8028[Abstract/Free Full Text]
|
| 26.
|
Burbelo, P. D.,
Drechsel, D.,
and Hall, A.
(1995)
J. Biol. Chem.
270,
29071-29074[Abstract/Free Full Text]
|
| 27.
|
Manser, E.,
Leung, T.,
Salihuddin, H.,
Tan, L.,
and Lim, L.
(1993)
Nature
363,
364-367[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Aspenström, P.,
Lindberg, U.,
and Hall, A.
(1996)
Curr. Biol.
6,
70-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kolluri, R.,
Tolias, K. F.,
Carpenter, C. L.,
Rosen, F. S.,
and Kirchhausen, T.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5615-5618[Abstract/Free Full Text]
|
| 30.
|
Chou, M. M.,
and Blenis, J.
(1996)
Cell
85,
573-583[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Fanger, G. R.,
Johnson, N. L.,
and Johnson, G. L.
(1997)
EMBO J.
16,
4961-4972[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Zhao, Z. S.,
Manser, E.,
Chen, X.-Q.,
Chong, C.,
Leung, T.,
and Lim, L.
(1998)
Mol. Cell. Biol.
18,
2153-2163[Abstract/Free Full Text]
|
| 33.
|
Knaus, U. G.,
Wang, Y.,
Reilly, A. M.,
Warnock, D.,
and Jackson, J. H.
(1998)
J. Biol. Chem.
273,
21512-21518[Abstract/Free Full Text]
|
| 34.
|
Zenke, F. T.,
King, C. C.,
Bohl, B. P.,
and Bokoch, G. M.
(1999)
J. Biol. Chem.
274,
32565-32573[Abstract/Free Full Text]
|
| 35.
|
Gallo, K. A.,
Mark, M. R.,
Scadden, D. T.,
Wang, Z.,
Gu, Q.,
and Godowski, P. J.
(1994)
J. Biol. Chem.
269,
15092-15100[Abstract/Free Full Text]
|
| 36.
|
Ing, Y. L.,
Leung, I. W. L.,
Heng, H. H. Q.,
Tsui, L.-C.,
and Lassam, N. J.
(1994)
Oncogene
9,
1745-1750[Medline]
[Order article via Infotrieve]
|
| 37.
|
Ezoe, K.,
Lee, S. T.,
Strunk, K. M.,
and Spritz, R. A.
(1994)
Oncogene
9,
935-938[Medline]
[Order article via Infotrieve]
|
| 38.
|
Rana, A.,
Gallo, K.,
Godowski, P.,
Hirai, S.,
Ohno, S.,
Zon, L.,
Kyriakis, J. M.,
and Avruch, J.
(1996)
J. Biol. Chem.
271,
19025-19028[Abstract/Free Full Text]
|
| 39.
|
Whitmarsh, A. J.,
Cavanagh, J.,
Tournier, C.,
Yasuda, J.,
and Davis, R. J.
(1998)
Science
281,
1671-1674[Abstract/Free Full Text]
|
| 40.
|
Tibbles, L. A.,
Ing, Y. L.,
Kiefer, F.,
Chan, J.,
Iscove, N.,
Woodgett, J. R.,
and Lassam, N. J.
(1996)
EMBO J.
15,
7026-7035[Medline]
[Order article via Infotrieve]
|
| 41.
|
Hartkamp, J.,
Troppmair, J.,
and Rapp, U. R.
(1999)
Cancer Res.
59,
2195-2202[Abstract/Free Full Text]
|
| 42.
|
Teramoto, H.,
Coso, O. A.,
Miyata, H.,
Igishi, T.,
Miki, T.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
27225-27228[Abstract/Free Full Text]
|
| 43.
|
Dickens, M.,
Rogers, J. S.,
Cavanagh, J.,
Raitano, A.,
Xia, Z.,
Halpern, J. R.,
Greenberg, M. E.,
Sawyers, C. L.,
and Davis, R. J.
(1997)
Science
277,
693-696[Abstract/Free Full Text]
|
| 44.
|
Yasuda, J.,
Whitmarsh, A. J.,
Cavanagh, J.,
Sharma, M.,
and Davis, R. J.
(1999)
Mol. Cell. Biol.
19,
7245-7254[Abstract/Free Full Text]
|
| 45.
|
Higuchi, R.
(1990)
in
PCR Protocols: A Guide to Methods and Applications
(Innis, M. A.
, Gelfand, D. H.
, Sninsky, J. J.
, and White, T. J., eds)
, pp. 177-183, Academic Press, Inc., San Diego, CA
|
| 46.
|
Gorman, C.
(1990)
in
DNA Cloning: A Practical Approach
(Glover, D. M., ed)
, pp. 143-190, IRL Press, Washington, D. C.
|
| 47.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hanks, S. K.,
Quinn, A. M.,
and Hunter, T.
(1988)
Science
241,
42-52[Abstract/Free Full Text]
|
| 49.
|
Kanakura, Y.,
Druker, B.,
Wood, K. W.,
Mamon, H. J.,
Okuda, K.,
Roberts, T. M.,
and Griffin, J. D.
(1991)
Blood
77,
243-248[Abstract/Free Full Text]
|
| 50.
|
Tamaki, T.,
Kanakura, Y.,
Kuriu, A.,
Ikeda, H.,
Mitsui, H.,
Yagura, H.,
Matsumura, I.,
Druker, B.,
Griffin, J. D.,
and Kanayama, Y.
(1992)
Cancer Res.
52,
566-570[Abstract/Free Full Text]
|
| 51.
|
Rudolph, M. G.,
Bayer, P.,
Abo, A.,
Kuhlmann, J.,
Vetter, I. R.,
and Wittinghofer, A.
(1998)
J. Biol. Chem.
273,
18067-18076[Abstract/Free Full Text]
|
| 52.
|
Thompson, G.,
Owen, D.,
Chalk, P. A.,
and Lowe, P. N.
(1998)
Biochemistry
37,
7885-7891[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Sells, M. A.,
and Chernoff, J.
(1997)
Trends Cell Biol.
7,
162-167
|
| 54.
|
Nagata, K.,
Puls, A.,
Futter, C.,
Aspenström, P.,
Schaefer, E.,
Nakata, T.,
Hirokawa, N.,
and Hall, A.
(1998)
EMBO J.
17,
149-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Mott, H. R.,
Owen, D.,
Nietlispach, D.,
Lowe, P. N.,
Manser, E.,
Lim, L.,
and Laue, E. D.
(1999)
Nature
399,
384-388[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Miki, H.,
Sasaki, T.,
Takai, Y.,
and Takenawa, T.
(1998)
Nature
391,
93-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Abdul-Manan, N.,
Aghazadeh, B.,
Liu, G. A.,
Majumdar, A.,
Ouerfelli, O.,
Siminovitch, K. A.,
and Rosen, M. K.
(1999)
Nature
399,
379-383[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Leung, I. W. L.,
and Lassam, N.
(1998)
J. Biol. Chem.
273,
32408-32415[Abstract/Free Full Text]
|
| 59.
|
Boyle, W. J.,
Van der Geer, P.,
and Hunter, T.
(1991)
Methods Enzymol.
201,
110-149[Medline]
[Order article via Infotrieve]
|
| 60.
|
Maltese, W. A.,
and Sheridan, K. M.
(1990)
J. Biol. Chem.
265,
17883-17890[Abstract/Free Full Text]
|
| 61.
|
Erickson, J. W.,
Zhang, C.,
Kahn, R. A.,
Evans, T.,
and Cerione, R. A.
(1996)
J. Biol. Chem.
271,
26850-26854[Abstract/Free Full Text]
|
| 62.
|
Backlund, P.
(1993)
Biochem. Biophys. Res. Commun.
196,
534-542[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Hart, M. J.,
Polakis, P. G.,
Evans, T.,
and Cerione, R. A.
(1990)
J. Biol. Chem.
265,
5990-6001[Abstract/Free Full Text]
|
| 64.
|
Dash, D.,
Aepfelbacher, M.,
and Siess, W.
(1995)
J. Biol. Chem.
270,
17321-17326[Abstract/Free Full Text]
|
| 65.
|
King, A. J.,
Sun, H.,
Diaz, B.,
Barnard, D.,
Miao, W.,
Bagrodia, S.,
and Marshall, M. S.
(1998)
Nature
396,
180-183[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Kiefer, F.,
Tibbles, L. A.,
Anafi, M.,
Janssen, A.,
Zanke, B. W.,
Lassam, N.,
Pawson, T.,
Woodgett, R. J.,
and Iscove, N. N.
(1996)
EMBO J.
15,
7013-7025[Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Polaski, L. Whitney, B. W. Barker, and B. Stronach
Genetic Analysis of Slipper/Mixed Lineage Kinase Reveals Requirements in Multiple Jun-N-Terminal Kinase-Dependent Morphogenetic Events During Drosophila Development
Genetics,
October 1, 2006;
174(2):
719 - 733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Schachter, Y. Du, A. Lin, and K. A. Gallo
Dynamic Positive Feedback Phosphorylation of Mixed Lineage Kinase 3 by JNK Reversibly Regulates Its Distribution to Triton-soluble Domains
J. Biol. Chem.,
July 14, 2006;
281(28):
19134 - 19144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Du, B. C. Bock, K. A. Schachter, M. Chao, and K. A. Gallo
Cdc42 Induces Activation Loop Phosphorylation and Membrane Targeting of Mixed Lineage Kinase 3
J. Biol. Chem.,
December 30, 2005;
280(52):
42984 - 42993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-Y. Kim, B.-C. Kim, Z. Xu, and S.-J. Kim
Mixed Lineage Kinase 3 (MLK3)-activated p38 MAP Kinase Mediates Transforming Growth Factor-{beta}-induced Apoptosis in Hepatoma Cells
J. Biol. Chem.,
July 9, 2004;
279(28):
29478 - 29484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang, W. Wu, Y. Du, S. J. Santos, S. E. Conrad, J. T. Watson, N. Grammatikakis, and K. A. Gallo
Hsp90/p50cdc37 Is Required for Mixed-lineage Kinase (MLK) 3 Signaling
J. Biol. Chem.,
May 7, 2004;
279(19):
19457 - 19463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. SCHMITZ, S. BACHER, and O. DIENZ
NF-{kappa}B activation pathways induced by T cell costimulation
FASEB J,
December 1, 2003;
17(15):
2187 - 2193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Shen, J. Godlewski, J. Zhu, P. Sathyanarayana, V. Leaner, M. J. Birrer, A. Rana, and G. Tzivion
Cross-talk between JNK/SAPK and ERK/MAPK Pathways: SUSTAINED ACTIVATION OF JNK BLOCKS ERK ACTIVATION BY MITOGENIC FACTORS
J. Biol. Chem.,
July 11, 2003;
278(29):
26715 - 26721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. I. Swenson, K. E. Winkler, and A. R. Means
A New Identity for MLK3 as an NIMA-related, Cell Cycle-regulated Kinase That Is Localized near Centrosomes and Influences Microtubule Organization
Mol. Biol. Cell,
January 1, 2003;
14(1):
156 - 172.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Stronach and N. Perrimon
Activation of the JNK pathway during dorsal closure in Drosophila requires the mixed lineage kinase, slipper
Genes & Dev.,
February 1, 2002;
16(3):
377 - 387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang and K. A. Gallo
Autoinhibition of Mixed Lineage Kinase 3 through Its Src Homology 3 Domain
J. Biol. Chem.,
November 30, 2001;
276(49):
45598 - 45603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Xu, A. C. Maroney, P. Dobrzanski, N. V. Kukekov, and L. A. Greene
The MLK Family Mediates c-Jun N-Terminal Kinase Activation in Neuronal Apoptosis
Mol. Cell. Biol.,
July 15, 2001;
21(14):
4713 - 4724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mota, M. Reeder, J. Chernoff, and C. E. Bazenet
Evidence for a Role of Mixed Lineage Kinases in Neuronal Apoptosis
J. Neurosci.,
July 15, 2001;
21(14):
4949 - 4957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Vacratsis and K. A. Gallo
Zipper-mediated Oligomerization of the Mixed Lineage Kinase SPRK/MLK-3 Is Not Required for Its Activation by the GTPase cdc 42 but Is Necessary for Its Activation of the JNK Pathway. MONOMERIC SPRK L410P DOES NOT CATALYZE THE ACTIVATING PHOSPHORYLATION OF Thr258 OF MURINE MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4
J. Biol. Chem.,
September 1, 2000;
275(36):
27893 - 27900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Maroney, J. P. Finn, T. J. Connors, J. T. Durkin, T. Angeles, G. Gessner, Z. Xu, S. L. Meyer, M. J. Savage, L. A. Greene, et al.
CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family
J. Biol. Chem.,
June 29, 2001;
276(27):
25302 - 25308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Cao, A. V. Medvedev, K. W. Daniel, and S. Collins
beta -Adrenergic Activation of p38 MAP Kinase in Adipocytes. cAMP INDUCTION OF THE UNCOUPLING PROTEIN 1 (UCP1) GENE REQUIRES p38 MAP KINASE
J. Biol. Chem.,
July 13, 2001;
276(29):
27077 - 27082.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|